Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R788 (Fostamatinib) in Chronic Idiopathic Thrombocytopenic Purpura
NCT04132050Phase 3Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing R788 Arm with Placebo Arm (2 arms). Primary endpoint: Achievement Rate of Stable Platelet Response at 24 weeks. Started Dec 2019; status: completed.
02
Drugs
fostamatinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04132050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04132050.